Skip to main content
AmigoFish

Ep. 395 - ESMO analysis & Auchincloss proposal

From BioCentury This Week · · 33 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts (https://www.biocentury.com/article/661354) discuss why new targets alone may not be enough to overcome resistance. Turning to policy, the analysts examine Representative Jake Auchincloss’ Faster Clinical Trials (https://www.biocentury.com/article/661390) Act, which would embed trials in routine care and expand the NIH's All of Us biobank. They also discuss how U.S. investors are reacting to Treasury's proposed COINS Act (https://www.biocentury.com/article/661332) rule, including a workaround that pays Chinese licensors on exit instead of with equity, and former FDA Commissioner Janet Woodcock's proposals (https://www.biocentury.com/article/661302) to make individualized rare disease therapies commercially viable.

View full story: https://www.biocentury.com/article/661405

#ADCs #ClinicalTrials #BiotechPolicy #ChinaBiotech #RareDisease

0:00 Introduction 1:34 ESMO First-in-Human Analysis 10:26 Faster Clinical Trials Act 19:27 COINS Act and NewCos 28:19 Woodcock's Rare Disease Proposals 31:53 Biotech IPO Debuts

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem